Want to see NUTX full AI Analyst Report?
NUTX Stock Chart & Stats
$188.10
-$7.69(-5.01%)
At close: 4:00 PM EDT
$188.10
-$7.69(-5.01%)
Day’s Range― - ―
52-Week Range$83.99 - $224.28
Previous Close$145.87
Volume132.68K
Average Volume (3M)147.41K
Market Cap
$1.45B
Enterprise Value$1.45K
Total Cash (Recent Filing)$205.21M
Total Debt (Recent Filing)$347.34M
Price to Earnings (P/E)8.1
Beta2.08
Next Earnings
Nov 24, 2026EPS Estimate
5.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)26.23
Shares Outstanding6,847,973
10 Day Avg. Volume154,533
30 Day Avg. Volume147,406
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)3.18
Price to Sales (P/S)1.20
P/FCF Ratio4.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$285.25Price Target Upside51.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)28.3
Revenue Forecast (FY)$869.68M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationImproving operating cash flow and a larger cash balance show that recent earnings are translating into liquidity. This strengthens Nutex’s ability to fund hospital development, absorb operating variability, and reduce reliance on external capital over the next several quarters.
Improved Profitability And MarginsThe sharp move from prior losses to substantial net income indicates stronger current earnings power, while the higher gross margin supports operating leverage. If these improvements persist, Nutex should have greater capacity to reinvest and strengthen its financial position.
Patient-volume GrowthGrowing hospital visits, including positive same-hospital performance, provide an underlying utilization base for revenue and earnings. This operational momentum is more durable than a single-period accounting benefit and supports continued network expansion and service-line development.
Bears Say
Reported Revenue ContractionRevenue contraction weakens confidence in the durability of Nutex’s growth profile, even though management attributes part of the comparison to prior IDR catch-up effects. Sustained softness could limit operating leverage and make strong recent profitability harder to maintain.
Higher Accounts ReceivableThe increase in receivables creates greater exposure to collection timing and cash-conversion variability. Although recent operating cash flow is strong, a larger receivables balance can delay liquidity realization and raise execution pressure around payer collections and dispute resolution.
Cybersecurity And Data ExposureA cybersecurity incident involving potentially sensitive patient, employee, provider, financial, and intellectual-property data creates ongoing legal, regulatory, and reputational exposure. The company has not identified a material operational impact so far, but assessment and required notifications remain unresolved.
Clinigence Holdings News
NUTX FAQ
What was Clinigence Holdings’s price range in the past 12 months?
Clinigence Holdings lowest stock price was $83.99 and its highest was $224.28 in the past 12 months.
What is Clinigence Holdings’s market cap?
Clinigence Holdings’s market cap is $1.45B.
When is Clinigence Holdings’s upcoming earnings report date?
Clinigence Holdings’s upcoming earnings report date is Nov 24, 2026 which is in 53 days.
How were Clinigence Holdings’s earnings last quarter?
Clinigence Holdings released its earnings results on Aug 06, 2026. The company reported $9.38 earnings per share for the quarter, beating the consensus estimate of $4.954 by $4.426.
Is Clinigence Holdings overvalued?
According to Wall Street analysts Clinigence Holdings’s price is currently Undervalued.
Does Clinigence Holdings pay dividends?
Clinigence Holdings does not currently pay dividends.
What is Clinigence Holdings’s EPS estimate?
Clinigence Holdings’s EPS estimate is 5.71.
How many shares outstanding does Clinigence Holdings have?
Clinigence Holdings has 6,847,973 shares outstanding.
What happened to Clinigence Holdings’s price movement after its last earnings report?
Clinigence Holdings reported an EPS of $9.38 in its last earnings report, beating expectations of $4.954. Following the earnings report the stock price went up 6.674%.
Which hedge fund is a major shareholder of Clinigence Holdings?
Currently, no hedge funds are holding shares in NUTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clinigence Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$285.25 (51.65% Upside)
$285.25 (51.65% Upside)
Blogger Sentiment
Bullish
NUTX Sentiment 75%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 21.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $43.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▲ 24.3%
Last 30 Days ▲ 24.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.70%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Clinigence Holdings
Nutex Health, Inc. functions as a technology-powered enterprise delivering healthcare services, structured into two key segments: its Hospital division and its Population Health Management division. The Hospital division is tasked with developing and overseeing various healthcare models, encompassing micro-hospitals, specialized medical centers, and hospital outpatient facilities. This segment currently owns and operates 21 locations spanning eight different states. Meanwhile, the Population Health Management division establishes and manages provider networks, such as independent physician associations. Additionally, its management services organizations furnish administrative, operational, and support assistance to its associated hospitals and physician groups. A proprietary, cloud-based technology platform within this division is crucial; it aggregates patient and provider data from multiple information systems, settings, and sources to construct a holistic view, thereby enabling more effective care delivery. The company maintains its corporate headquarters in Houston, Texas.
NUTX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple meaningful operational and financial positives: a large jump in net income driven by lower non-cash/one-time expenses (notably stock-based compensation swing), stronger adjusted EBITDA and operating income, cash-flow improvement, meaningful cost reductions tied to the HaloMD amendment and a CMS IDR fee cut, sustained patient-volume growth and an active de novo development pipeline. Offsetting these positives were declines in reported revenue year-over-year (largely explained by prior-period IDR catch-up effects), higher G&A as a percent of revenue, and slower-than-desired insurer behavior and contract progress. On balance, the scale and persistence of the liquidity, profitability, arbitration cost savings, and volume improvements outweigh the revenue comparability headwinds and insurer uncertainties.View all NUTX earnings summariesNUTX Stock 12 Month Forecast
Average Price Target
$285.25
▲(51.65% Upside)
Technical Analysis
AMN Healthcare Services
―
Pennant Group
―
InnovAge Holding
―
Agilon Health
―
Ardent Health Partners, Inc.
―
Ownership Overview
32.76% Insiders
6.90% Mutual Funds
10.32% Other Institutional Investors
34.58% Public Companies and
Individual Investors